Acquiring to grow
Solvay Pharmaceuticals wants to accelerate growth and to provide patients with faster access to important treatments. In general to be successful in a territory, Solvay Pharmaceuticals sets up its own branch office or legal entity there. In most cases we prefer to acquire a running company and then convert it into a Solvay Pharma selling organization. But we may also start with a local agency or a host-partner relationship and build it up.

With the successful acquisition of Neopharma and its Parkinson’s medication Duodopa® we reinforced our activities in the field of Parkinson’s disease. Together with its own research, Solvay will be able to provide remedies to millions of Parkinson’s sufferers across the world, at every stage of the disease.

The acquisition of the French global leader in fenofibrate, Fournier Pharma in 2005, was a major strategic move to accelerate sustainable profitable growth. 
Fournier Pharma is the global leader in fenofibrate, a successful cardio-metabolic product for treating raised blood lipids. Fournier Pharma adds a strong and unique product line in dyslipidemia (i.e. control of cholesterol and triglycerides) to our cardiology business and research pipeline. It makes this new cardio-metabolic area our largest franchise.

In 2008, Solvay Pharmaceuticals took over the Belgium-based biotech company Innogenetics as part of its long-term growth strategy and to help accelarate its therapeutic pipeline through the implementatioin of biomarker, diagnostics and eventually companion diagnostics technologies.